Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2025-04-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
长城证券股份有限公司关于浙江泰林生物技术股份有限公司持续督导之2024年度培训情况报告
Audit Report / Information Classification · 95% confidence The document is a report from Great Wall Securities Co., Ltd. regarding the 2024 annual continuous supervision training conducted for Zhejiang Tailin Biotechnology Co., Ltd. It details the training content, participants, and outcomes related to regulatory compliance and market value management. The document is a specific report on a training activity related to regulatory supervision and compliance, not a financial report, earnings release, or announcement of voting results. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a standalone report related to regulatory supervision and training, which aligns best with Audit Report / Information (AR) as it involves regulatory compliance and supervisory activities. The document length is short but contains substantive content, so it is not a mere announcement. Therefore, the classification is AR with high confidence. FY 2024
2025-04-28 Chinese
关于2025年度董事、监事及高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2025 remuneration scheme for the company's directors, supervisors, and senior management. It details the salary standards, payment methods, and approval process for the remuneration plan. The content focuses on compensation information for top executives and board members, which aligns with the definition of Remuneration Information filings. The document is not a full report, financial statement, or meeting minutes, but a specific announcement about executive pay. Therefore, the appropriate classification is Remuneration Information (DEF 14A). The document length and content confirm it is not a brief announcement or a regulatory filing fallback.
2025-04-27 Chinese
关于2025年第一季度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (301 characters) stating that the company's 2025 first quarter report has been disclosed on an official website. It does not contain the actual financial data or detailed report content but merely informs investors where to find the report. According to the 'MENU VS MEAL' rule, such a brief notice about report availability is classified as a Report Publication Announcement (RPA).
2025-04-27 Chinese
监事会关于作废2022年限制性股票激励计划部分已授予尚未归属的限制性股票的审核意见
Board/Management Information Classification · 95% confidence The document is a supervisory board's audit opinion regarding the cancellation of certain unvested restricted stocks under the company's 2022 restricted stock incentive plan. It discusses compliance with relevant laws, regulations, and company rules, and provides an official opinion approving the cancellation. The document is not a financial report, earnings release, or management discussion, but rather a formal board-level opinion on a specific corporate governance matter related to stock incentives. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management regarding corporate governance or equity plans.
2025-04-27 Chinese
2024年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2024 年度财务决算报告' which translates to '2024 Annual Financial Settlement Report'. It contains detailed audited financial statements for the year 2024, including assets, liabilities, equity, operating results, and cash flow data. The audit opinion is from a certified accounting firm with a standard unqualified opinion, indicating this is a formal audited financial report. The presence of comprehensive financial data and audit information for a full fiscal year strongly indicates this is an Annual Report. The document length is 1477 characters, which is short but contains substantive financial data, so it is not merely an announcement or certification. Therefore, the correct classification is Annual Report (10-K). FY 2024
2025-04-27 Chinese
关于作废2022年限制性股票激励计划部分已授予尚未归属的限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the cancellation of part of the restricted stock granted but not yet vested under the 2022 restricted stock incentive plan. It details board and supervisory committee meetings, legal opinions, and the specific reasons for the cancellation (employee departures and unmet performance targets). The document is a formal announcement about changes in the company's stock incentive plan, specifically the cancellation of restricted stock awards. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is not a shareholder meeting material or voting result announcement. It is a regulatory announcement about a corporate action related to stock incentives. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-27 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.